FeesSafety
Pluang+

TruBridge menghadapi gugatan class action setelah mengungkapkan kesalahan akuntansi yang menyebabkan sahamnya anjlok 10,5%.

Market News
15 Sep 2026
PRNewsWire
View Source
Bearish
TruBridge menghadapi gugatan class action setelah mengungkapkan kesalahan akuntansi yang menyebabkan sahamnya anjlok 10,5%.

Rosen Law Firm sedang menyelidiki potensi klaim sekuritas terhadap TruBridge, Inc. setelah perusahaan tersebut mengungkapkan adanya kesalahan akuntansi pada laporan keuangan sebelumnya. Kesalahan ini terkait dengan pengakuan pendapatan, biaya terkait kontrak, beban kompensasi berbasis saham, dan beban pengembangan perangkat lunak yang dikapitalisasi. Akibat pengungkapan ini, harga saham TruBridge turun 10,5% pada 17 Maret 2026. Firma hukum tersebut sedang mempersiapkan gugatan class action untuk memulihkan kerugian investor.

For readers following the TruBridge, Inc. securities class action investigation, here is Pluang's market snapshot as of Sep 16, 2026 08:21 WIB: of 150 priced Technology-sector US stocks tradable on Pluang, 54 rose and 94 fell today. Among them, Robinhood Markets, Inc. (HOOD) saw a 1-day change of -4.77% at USD 108.88, Hut 8 Corp (HUT) changed -4.67% at USD 86.87, and SoundHound AI Inc (SOUN) changed -4.64% at USD 6.17.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
1 hour ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
2 hours ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
2 hours ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
2 hours ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App